Cochlear's 70% Collapse Splits Fund Managers on Bubble vs Overreaction

Four consecutive downgrades wiped out years of gains, leaving short sellers vindicated and long-term believers betting the reaction went too far.

31 Aug 2026 · 4 min read

Cochlear suffered one of the most dramatic collapses on the ASX in 2026, falling nearly 70 percent from above $288 in October to below $94 by April after four consecutive earnings downgrades culminating in a single-day fall of more than 40 percent. What followed was a genuine debate between short sellers calling the former market darling's old valuation absurd and long-term believers arguing the world's leading cochlear implant maker had simply been oversold.

Four downgrades in a row

Blackwattle Investment Partners described a soft February result with revenue through to net profit missing expectations by a mid-single-digit margin, as management cut guidance to the low end of its $435 million to $460 million range, blaming a slower rollout of the new Nucleus Nexa implant system. First Sentier Investors said the stock fell 34.3 percent on that result, with implant volumes up 6 percent year on year but revenue down 2 percent in constant currency terms, reflecting delays in product registrations and contract renewals tied to the Nexa launch. The bigger shock came in April. Ellerston Capital said the market was totally stunned as Cochlear lowered FY26 guidance by a staggering 30 percent, citing weak developed market trading, Middle East uncertainty, a stronger Australian dollar, structural pressure in European health systems, lower overhead recoveries, restructuring costs and reimbursement headwinds in China. Selector Funds Management detailed the scale of the cut, with underlying net profit guidance falling to $290 million to $330 million from $435 million to $460 million, implying a second-half NPAT of just $115 million against earlier expectations of $240 million, a figure severe enough to explain the more than 40 percent single-day share price fall. Hyperion Asset Management called it Cochlear's fourth consecutive downgrade, raising real questions about whether the pressures are cyclical or structural.

This is Cochlear's fourth consecutive downgrade, raising questions around cyclical vs. structural industry pressures.

— Hyperion Asset Management, Monthly Report, April 2026

A former darling gets punished for its old valuation

Regal Funds Management's King said Cochlear is a great example of a stock that became extremely overvalued, trading on a huge growth multiple even when it had no growth, arguing the flood of money into passive strategies has left many of the ASX's biggest companies overvalued, so that when they disappoint there is no valuation support left to catch the fall, a dynamic that fuelled gains on Regal's short position. Milford Asset Management called it simply a former market darling, and said not owning the stock was a positive contributor to its own performance. Blackwattle Investment Partners, underweight the sector, said the fair value of health care as a whole is now in question, given companies have continued to disappoint while still trading at a premium to offshore peers.

Cochlear is a great example of a stock that got extremely overvalued, it was trading on a huge growth multiple when it had no growth. So when they disappoint, there's no valuation support.

— Regal Funds Management, Article, May 2026

Bulls argue the sell-off went too far

Perennial Partners added to its relatively small holding in April, arguing valuation had become more attractive than it had been in some time, and by June the stock was up 21.1 percent, with Perennial noting Cochlear has stumbled recently but remains a global leader in a growing market and a very high-quality business overall. Cadence Capital initiated and added to a position, describing Cochlear as a former market darling on extreme valuations that had not met its fundamental criteria, but believing it remains a good business capable of turning around as the share price trend began to reverse. Australian Eagle Asset Management said its long position fell 40 percent in April before recovering almost 25 percent in June, as the market judged the initial sell-off excessive relative to Cochlear's global market dominance and structural growth drivers.

The debate over discretionary demand

Elston Asset Management framed the key debate as being about the discretionary nature of Cochlear's products, not in an economic sense but a behavioural one, since rehabilitation after implant surgery is lengthy and more patients have recently chosen to defer treatment, creating uncertainty that has driven both reduced revenue growth expectations and a material de-rating. Antares Capital traced the weakness to affordability constraints, with out-of-pocket costs remaining a key barrier it does not expect to improve near term. Ten Cap named Cochlear a guest pick in June while disclosing a caveat that one further small downgrade could still be coming, expecting management to set conservative guidance for the year ahead given how badly it has missed in the past.

What fund managers say they are watching next is whether the deferred-treatment and affordability dynamic proves cyclical or structural, whether Cochlear can deliver against its heavily reset guidance without a fifth downgrade, how quickly the Nexa implant system's rollout translates into actual sales, and whether the broader healthcare sector's premium valuation relative to offshore peers gets resolved alongside Cochlear's own recovery.